Tianfeng Securities: Initiates "Buy" rating for KHPG with a target price of 51.84 yuan

KHPG: Ipasitide tablets have obtained a drug registration certificate

According to the Zhitong Finance APP, KHPG announced that the company recently received the "Drug Registration Certificate" for Ipatasertib tablets issued by the National Medical Products Administration, approving its registration. The indication for this medication is diabetic neuropathy

KHPG: Criminals are using the company's name to carry out fraud and other activities

KHPG issued a statement on the evening of August 12, stating that recent illegal activities have involved criminals impersonating the company to conduct fraud. The company emphasized that it has not engaged in any sales of investment products and has not authorized any third parties to conduct such sales. KHPG warns against these illegal activities and will report the relevant criminals, reserving the right to pursue legal responsibility

The concept of innovative drugs has strengthened again, with Hotgen rising over 10% to reach a new historical high

In the morning session, the innovative drug concept strengthened again, with Hotgen rising over 10%, reaching a historical high. Junshi Biosciences and Hongbo Medicine also rose over 10%, while Chenxin Pharmaceutical, KHPG, HITECK, BIO-THERA, and JENKEM followed suit

KHPG: Currently, production and business activities are normal, and there are no significant matters that should be disclosed but have not been disclosed

KHPG announced that its stock price has fluctuated by more than 20% recently, but the company's operations are normal and there have been no significant changes. The company and its controlling shareholders, as well as actual controllers, do not have any undisclosed significant matters